Sodium Bicarbonate → 4-(3,5-dimethyl-1-((3-methyloxetan-3-yl)methyl)-1H-pyrazol-4-yl)-6-(trifluoromethyl)-1H-indazole

HRID 58107

Reaction equation

HRID 58107 reaction equation
CC1(C)C(C)(C)OB([C:9]2[CH:17]=[C:16]([C:18]([F:21])([F:20])[F:19])[CH:15]=[C:14]3[C:10]=2[CH:11]=[N:12][NH:13]3)O1.Br[C:24]1[C:25]([CH3:36])=[N:26][N:27]([CH2:30][C:31]2([CH3:35])[CH2:34][O:33][CH2:32]2)[C:28]=1[CH3:29].[C:37](=[O:40])(O)[O-:38].[Na+]>C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.Cl[Pd]Cl.[Fe+2].O1CCOCC1>[C:37]([OH:38])([C:18]([F:21])([F:20])[F:19])=[O:40].[CH3:36][C:25]1[C:24]([C:9]2[CH:17]=[C:16]([C:18]([F:19])([F:20])[F:21])[CH:15]=[C:14]3[C:10]=2[CH:11]=[N:12][NH:13]3)=[C:28]([CH3:29])[N:27]([CH2:30][C:31]2([CH3:35])[CH2:34][O:33][CH2:32]2)[N:26]=1

Participants

7

Reactant 3

HCID 516892Sodium BicarbonateHCID 897828064-(Tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)-1H-indazoleHCID 897828264-Bromo-3,5-dimethyl-1-[(3-methyl-3-oxetanyl)methyl]-1H-pyrazole

Product 2

HCID 6422Trifluoroacetic acidHCID 897834294-(3,5-dimethyl-1-((3-methyloxetan-3-yl)methyl)-1H-pyrazol-4-yl)-6-(trifluoromethyl)-1H-indazoleYield 28.5%

Reagents, catalysts & solvents 2

HCID 178418228Bis(cyclopenta-1,4-dien-1-yl(diphenyl)phosphane);dichloropalladium;iron(2+)CatalystHCID 312751,4-DioxaneSolvent

Conditions

Temperature
140 °C

Procedure

To a 5 mL vial equipped with a magnetic stir bar were added 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)-1H-indazole (41.6 mg, 0.133 mmol), 4-bromo-3,5-dimethyl-1-((3-methyloxetan-3-yl)methyl)-1H-pyrazole (51.8 mg, 0.2 mmol), sodium bicarbonate (0.285 mL, 0.533 mmol), PdCl2(dppf) (9.76 mg, 0.013 mmol), and dioxane (3 mL). The contents of the vial were stirred to give an orange suspension. The vial was sealed and then heated in a microwave reactor at 140° C. for 90 minutes. The reaction mixture was subsequently filtered and the product was purified by preparative HPLC, eluting with a gradient of 25-50% ACN (containing 0.035% TFA) in H2O (containing 0.05% TFA). The pure fractions were lyophilized to give a TFA salt of the title compound as a clear glass (6.9 mg, 11%). 1H NMR (400 MHz, CD3OD) δ ppm 1.46 (s, 3H), 2.37 (s, 6H), 3.71 (s, 2H), 4.31 (d, J=11.37 Hz, 2H), 4.58 (d, J=11.37 Hz, 2H), 7.39 (d, J=1.01 Hz, 1H), 8.04-8.06 (m, 1H), 8.07 (d, J=0.76 Hz, 1H); ESI-MS m/z [M+H]+ calc'd for C18H19F3N4O, 365.2. found 365.3.

Workup

  1. customTo a 5 mL vial equipped with a magnetic stir bar
  2. customto give an orange suspension
  3. customThe vial was sealed
  4. filtrationThe reaction mixture was subsequently filtered
  5. customthe product was purified by preparative HPLC
  6. washeluting with a gradient of 25-50% ACN (containing 0.035% TFA) in H2O (containing 0.05% TFA)

Sources & evidence

ORD record
ord-3485b525722f41fcacba80e09e92f30d
Source dataset
uspto-grants-2016_09
Patent number
US09434743B2

Linked notes

Loading…